Searched for
LUPIN INHALATION DRUG
Lupin to set up new facility in US with an investment of USD 250 mnDrug firm Lupin will establish a new manufacturing plant in Coral Springs, Florida. The investment totals USD 250 million over five years. ...- Lupin inks licensing deal to supply biosimilar ranibizumab in Latin AmericaLupin, an Indian drug maker, partners with SteinCares. The agreement focuses on ranibizumab's commercialisation. Latin America, excluding M...
- Lupin unit introduces inhaler for asthma patients in GermanyDrug firm Lupin on Friday said its unit has launched a pressurized metered dose inhaler for the treatment of asthma and chronic obstructive...
- Lupin inks pact to acquire two inhalation brands from Sunovion for USD 75 mnThe acquisition of these two brands will expand the company's inhalation product portfolio in the US and strengthen its presence in the res...
- Lupin acquires exclusive rights to develop, manufacture TTP inhalation productsBy leveraging this technology, Lupin expects to provide healthcare professionals with alternative solutions for delivering affordable inhal...
- Lupin launches digital asthma educator platformThe new platform is the latest initiative under Lupin's long running umbrella programme, Joint Airways Initiative (JAI), for patients suffe...
- Lupin gets US health regulator's approval for asthmatic symptoms prevention drugThe approved product is a generic version of ProAir HFA of Teva Branded Pharmaceutical Products R&D, Inc. In a regulatory filing, Lupin sai...
- Lupin aims to launch new products across geographies this fiscal"Looking ahead, FY2020 is an exciting year for Lupin as we plan to bring our first biosimilar to market," company said.
- Lupin's Pithampur unit gets inspection closure report from USFDAPithampur Unit-3 facility is involved in the manufacture of metered dose inhalers.
- Lupin gets EIR from USFDA for Pithampur facility unitLupin's Pithampur facility manufactures dermatological products, dry product inhalers, and metered dose inhalers.
- Lupin gets USFDA nod for Asthma drugQuoting IQVIA MAT September data, Lupin said, the said Asthma drug had annual sales of around USD 474.5 million in the US.
- Lupin launches generic antibiotic inhalation solution in USThe company has launched the product as it has received an approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in...
- Lupin, Cipla, other top drugmakers in fray for Novartis’ brandsThe Novartis portfolio includes top-selling brand TOBI Podhaler, a drug prescribed for symptomatic relief to patients suffering from cystic...
- Lupin receives US FDA approval for Novartis genericTobramycin inhalation solution USP, 300 mg/5 ml, had sales of $133.6 million in the US as of December 2016, Lupin stated in a release about...
- Lupin to market Novartis' inhaler under Loftair brand nameAccording to IMS sales data, Lupin is ranked second with 12.4 per cent market share of the overall anti-asthma segment within the Indian ph...
- Lupin opens R&D facility to develop inhalation products in USDrug major Lupin today said it has opened a research and development centre for inhalation products in Florida, the US.
- Lupin launches asthma drug delivery device in USThe agreement grants Lupin exclusive rights to promote, distribute and market InspiraChamber VHC in the US, it added.
- Lupin ties up with Poland-based firm for generic asthama drugLupin has set up a dedicated centre of excellence for inhalation research in Florida after having hired top notch inhalation scientists las...
- Lupin rallies over 1% on acquisition plans, USFDA HIV drug approvalLupin Ltd rallied as much as 1.5 per cent in trade on Monday on reports that that the drug major is eyeing acquisitions in various global m...
- Lupin scouts for acquisitions in USCompany continues to be on the lookout for meaningful targets, be it brands or technology companies, in inhalation, complex injectables and...
Load More
